Processa Pharmaceuticals, Inc. (PCSA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PCSA Revenue Growth
PCSA Revenue Analysis (2014–2025)
As of May 8, 2026, Processa Pharmaceuticals, Inc. (PCSA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, PCSA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $200,201 in 2014.
When compared to Healthcare sector peers including NUVB (+1205.5% YoY), CASI (+21.7% YoY), and HALO (+37.6% YoY). Compare PCSA vs NUVB →
PCSA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCSACurrent | $0 | - | - | - | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 CASI | $29M | +21.7% | +47.2% | -138.8% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
PCSA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-1,204 | - | $-13,988,505 | - |
| 2024 | $0 | - | $0 | - | $-12,051,206 | - |
| 2023 | $0 | - | $0 | - | $-11,457,061 | - |
| 2022 | $0 | - | $0 | - | $-27,525,431 | - |
| 2021 | $0 | - | $0 | - | $-12,133,543 | - |
| 2020 | $0 | - | $-882,062 | - | $-15,136,859 | - |
| 2019 | $0 | - | $-877,897 | - | $-3,935,482 | - |
| 2018 | $0 | - | $-630,092 | - | $-4,524,940 | - |
| 2017 | $0 | -100.0% | $-1,865 | - | $-1,802,433 | - |
| 2016 | $5K | -95.6% | $4K | 72.4% | $-1,921,520 | -38430.4% |
See PCSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCSA — Frequently Asked Questions
Quick answers to the most common questions about buying PCSA stock.
Is PCSA's revenue growth accelerating or slowing?
PCSA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PCSA's long-term revenue growth rate?
Processa Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is PCSA's revenue distributed by segment?
PCSA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.